Overall survival is a widely accepted endpoint in phase 3 clinical trials of castration-resistant prostate cancer (CRPC). However, the use of this endpoint is becoming more difficult as more agents are shown to improve survival in patients with CRPC. This editorial describes the commonly used surrogates for overall survival in CRPC with a special emphasis on radiographic response.
|Original language||English (US)|
|Number of pages||3|
|State||Published - Sep 1 2011|
ASJC Scopus subject areas
- Cancer Research